Compare MESO & AVAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MESO | AVAH |
|---|---|---|
| Founded | 2004 | 1984 |
| Country | Australia | United States |
| Employees | 81 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | N/A | 2021 |
| Metric | MESO | AVAH |
|---|---|---|
| Price | $15.63 | $7.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | N/A | ★ $10.56 |
| AVG Volume (30 Days) | 265.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.55 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $2,024,506,000.00 |
| Revenue This Year | $644.56 | $21.81 |
| Revenue Next Year | $38.70 | $5.96 |
| P/E Ratio | ★ N/A | $32.86 |
| Revenue Growth | N/A | ★ 6.82 |
| 52 Week Low | $9.61 | $3.73 |
| 52 Week High | $21.50 | $10.32 |
| Indicator | MESO | AVAH |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 35.06 |
| Support Level | $14.35 | $3.81 |
| Resistance Level | $16.32 | $7.52 |
| Average True Range (ATR) | 0.55 | 0.26 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 57.09 | 16.10 |
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). Private Duty Services include private duty nursing (PDN) and pediatric therapy services. Revenue is derived from pediatric healthcare services provided to patients including private duty nursing and therapy services, adult home health and hospice services (collectively patient revenue) and from the delivery of enteral nutrition and other products to patients.